Positive.

From Nasdaq: 2025-05-01 07:27:00

The first-quarter reporting cycle shows positive results, with most companies beating estimates. However, macroeconomic uncertainty remains a concern, leading analysts to lower future earnings estimates. The Medical sector stands out with strong earnings growth, offering a cushion against market volatility due to tariffs.

Key medical product companies are showing recovery and growth in 2025, driven by AI integration and at-home medical solutions. Despite potential tariff impact, many MedTech firms report better-than-expected earnings and revenue growth, with significant year-over-year improvement in metrics.

Using the Zacks Stock Screener, companies like Hims & Hers Health, Globus Medical, QuidelOrtho, and Haemonetics are expected to beat earnings estimates this reporting cycle. The Medical sector’s earnings are projected to increase by 40% in the first quarter, with a sales growth of 8.3% year over year.

Investors can benefit from the Zacks methodology, combining a Zacks Rank of 1, 2, or 3 with a positive Earnings ESP for potential positive surprises in earnings reports. Research indicates a 70% chance of a positive earnings surprise with this combination.

Highlighted companies like Hims & Hers Health, Globus Medical, QuidelOrtho, and Haemonetics are expected to beat earnings estimates in the first quarter, with positive Earnings ESP figures for each. The Zacks Consensus Estimates show growth expectations for these companies compared to the previous year.

For investors looking for potential winners, companies like Hims & Hers Health, Globus Medical, QuidelOrtho, and Haemonetics have shown positive earnings surprises and growth in the Medical sector. These companies are expected to continue their growth trend in the first quarter of 2025.

Zacks Research Chief names a stock with high potential for significant gains, highlighting innovative financial firms with a growing customer base and advanced solutions. This top pick is expected to outperform previous stock picks, offering a promising investment opportunity for investors looking for growth.



Read more at Nasdaq:: 4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates